PTC Therapeutics
40°33′03″N 74°25′23″W / 40.550722°N 74.423071°W
| Company type | Public |
|---|---|
| Nasdaq: PTCT Russell 2000 Component | |
| Industry | Pharmaceuticals |
| Founded | January 1, 1998 |
| Headquarters | , U.S. |
| Website | ptcbio |
PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control (PTC) mechanisms in orphan diseases.
In September 2009, PTC entered into an agreement with Roche for the development of orally bioavailable small molecules for central nervous system diseases. PTC acquired the Bio-e platform in 2019.